Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Biochim Pol ; 57(2): 235-9, 2010.
Article in English | MEDLINE | ID: mdl-20532254

ABSTRACT

The novel MAO-B inhibitor PF9601N, its cytochrome P450-dependent metabolite FA72 and l-deprenyl were studied as potential peroxynitrite (ONOO(-)) scavengers and nitric oxide synthase (NOS) inhibitors. The scavenging activity of these compounds was evaluated by measuring the oxygen consumption through peroxynitrite-mediated oxidation of both linoleic acid and brain homogenate. FA72, PF9601N and l-deprenyl caused a concentration-dependent inhibition of ONOO(-)-induced linoleic acid oxidation with an IC(50) value of 60.2 microM, 82.8 microM and 235.8 microM, respectively. FA72 was the most potent also in inhibiting ONOO(-)-induced brain homogenate oxidation with an IC(50) value of 99.4 microM, while PF9601N and l-deprenyl resulted weaker inhibitors in the same experimental model, showing an IC(50) value of 164.8 and 112.0 microM, respectively. Furthermore, both the novel MAO-B inhibitor as well as its metabolite were able to strongly inhibit rat brain neuronal NOS (IC(50) of 183 microM and 192 microM, respectively), while l-deprenyl at the highest concentration used (3 mM), caused only a slight decrease of the enzyme activity. Moreover, inducible NOS was strongly inhibited by FA72 only. All these results suggest that PF9601N could be a promising therapeutic agent in neurodegenerative disorders such as Parkinson's disease.


Subject(s)
Antioxidants/pharmacology , Indoles/pharmacology , Monoamine Oxidase , Reactive Nitrogen Species/chemistry , Animals , Antioxidants/chemistry , Brain Chemistry , Indoles/chemistry , Monoamine Oxidase Inhibitors/chemistry , Monoamine Oxidase Inhibitors/pharmacology , Rats
2.
Exp Cell Res ; 314(16): 2965-74, 2008 Oct 01.
Article in English | MEDLINE | ID: mdl-18692498

ABSTRACT

Circulating endothelial progenitor cells (EPCs) can contribute to neovascularization, even if the mechanisms by which they interact with mature endothelial cells remain unclear. The interactions between human coronary artery endothelial cells (HCAECs) and peripheral blood mononuclear cells (PBMCs) during their early differentiation towards an EPC phenotype were investigated. A co-culture model, in which the two cell types share the same culture medium in the absence of any exogenous angiogenic stimulus, was used. The role of hypoxia was assessed by pretreating HCAECs with 3% O(2) before co-culture setting. Since we have previously shown that both adherent and suspended PBMCs display a significant increase in endothelial marker expression within the 2nd day of culture in an angiogenic environment, the role of HCAECs on early PBMC differentiation was evaluated in both adherent and suspended cell fractions. A 3-day co-culture period increased the expression of VEGF-R2, VE-cadherin, alpha(v)beta(3)- and alpha(5)-integrin in both the adherent and suspended PBMCs, assessed by cytofluorimetric analysis, and up-regulated VEGF-R1 mRNA assessed by real-time RT-PCR. HCAECs influenced PBMC adhesion, transendothelial migration and cell organization on Matrigel. Hypoxia modulated either PBMC differentiation or their functional properties. These data strongly suggest that endothelium may support the differentiation of PBMCs into EPCs.


Subject(s)
Cell Differentiation/physiology , Endothelial Cells/physiology , Leukocytes, Mononuclear/physiology , Animals , Antigens, CD/genetics , Antigens, CD/metabolism , Biomarkers/metabolism , Cadherins/genetics , Cadherins/metabolism , Cell Adhesion/physiology , Cell Hypoxia , Cell Movement/physiology , Cells, Cultured , Coculture Techniques , Collagen/metabolism , Drug Combinations , E-Selectin/genetics , E-Selectin/metabolism , Endothelial Cells/cytology , Humans , Integrin alpha5/genetics , Integrin alpha5/metabolism , Integrin alphaVbeta3/genetics , Integrin alphaVbeta3/metabolism , Integrin beta1/genetics , Integrin beta1/metabolism , Laminin/metabolism , Leukocytes, Mononuclear/cytology , Phenotype , Platelet Endothelial Cell Adhesion Molecule-1/genetics , Platelet Endothelial Cell Adhesion Molecule-1/metabolism , Proteoglycans/metabolism , Stem Cells/cytology , Stem Cells/physiology , Vascular Endothelial Growth Factor Receptor-1/genetics , Vascular Endothelial Growth Factor Receptor-1/metabolism , Vascular Endothelial Growth Factor Receptor-2/genetics , Vascular Endothelial Growth Factor Receptor-2/metabolism , von Willebrand Factor/genetics , von Willebrand Factor/metabolism
3.
Am J Physiol Heart Circ Physiol ; 293(4): H2140-7, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17660397

ABSTRACT

Catecholamines have been shown to be involved in vascular remodeling through the stimulation of alpha(1)-adrenoceptors (alpha(1)-ARs). Recently, it has been demonstrated that catecholamines can stimulate angiogenesis in pathological conditions, even if the mechanisms and the AR subtypes involved still remain unclear. We investigated the influence of hypoxia (3% O(2)) on the ability of picomolar concentrations of phenylephrine (PHE), which are unable to induce any vascular contraction, to induce a trophic effect in human endothelial cells through stimulation of the alpha(1D)-subtype ARs. PHE, at picomolar concentrations, significantly promoted pseudocapillary formation from fragments of human mature vessels in vitro. Exposure to hypoxia significantly potentiated this effect, which was inhibited by the selective alpha(1D)-AR antagonist BMY-7378 and by the nitric oxide synthase inhibitor L-NAME, suggesting that alpha(1D)-ARs were involved in this effect through activation of the nitric oxide pathway. Proliferation and migration of HUVEC were also affected by picomolar PHE concentrations. Again, these effects were significantly potentiated in cells exposed to hypoxia and were inhibited by BMY-7378 and by N(G)-nitro-L-arginine methyl ester. Conversely, the alpha(1A)-AR-selective antagonist (S)-(+)-niguldipine hydrochloride and the alpha(1B)-AR antagonist chloroethylclonidine dihydrochloride did not modify endothelial cell migration and proliferation in response to PHE. These results demonstrate that the stimulation of alpha(1D)-ARs, triggered by picomolar PHE concentrations devoid of any contractile vascular effects, induces a proangiogenic phenotype in human endothelial cells that is enhanced in a hypoxic environment. The role of alpha(1D)-ARs may become more prominent in the adaptive responses to hypoxic vasculature injury.


Subject(s)
Adrenergic alpha-Agonists/pharmacology , Cell Size/drug effects , Endothelial Cells/drug effects , Neovascularization, Physiologic/drug effects , Phenylephrine/pharmacology , Receptors, Adrenergic, alpha-1/drug effects , Umbilical Arteries/drug effects , Adrenergic Antagonists/pharmacology , Cell Hypoxia , Cell Movement/drug effects , Cell Proliferation/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Endothelial Cells/enzymology , Endothelial Cells/metabolism , Enzyme Inhibitors/pharmacology , Humans , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide/metabolism , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase/metabolism , Organ Culture Techniques , Piperazines/pharmacology , Receptors, Adrenergic, alpha-1/metabolism , Umbilical Arteries/enzymology , Umbilical Arteries/metabolism
4.
Clin Immunol ; 121(1): 74-80, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16914380

ABSTRACT

We investigated the effects of metastasis, surgery and chemotherapy on both circulating dendritic cells (DCs) and monocyte-derived-DCs (MoDCs) in colorectal cancer (CRC) patients. Metastatic or nonmetastatic CRC patients had significantly reduced DC subsets compared to healthy subjects (p < 0.001). These cells were significantly higher in metastatic than in nonmetastatic patients. MoDCs were significantly lower in metastatic than healthy and nonmetastatic subjects (p < 0.001). Surgically treated patients had nearly one-half circulating DC subsets compared to healthy subjects (p < 0.001) while no difference was found between unoperated and healthy subjects. MoDCs obtained from tumor-bearing were significantly higher than in operated subjects. In both cases, MoDCs were significantly lower than in healthy subjects (p < 0.001). Circulating DCs and MoDCs were significantly lower in CRC patients, with or without chemotherapy, compared to healthy subjects (p < 0.001). Compared to untreated, chemotherapy-treated patients had 30% fewer DC subsets and lower MoDCs. Characterization of circulating DC subsets and MoDCs may elucidate CRC patients' immune system status.


Subject(s)
Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/surgery , Dendritic Cells/drug effects , Dendritic Cells/pathology , Monocytes/drug effects , Monocytes/pathology , Aged , Aged, 80 and over , Cell Differentiation/drug effects , Cell Differentiation/immunology , Cells, Cultured , Colorectal Neoplasms/pathology , Dendritic Cells/immunology , Female , Humans , Leukocyte Count , Male , Middle Aged , Monocytes/immunology , Neoplasm Metastasis/drug therapy , Neoplasm Metastasis/prevention & control
5.
Br J Pharmacol ; 146(4): 568-75, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16086034

ABSTRACT

We have previously shown that hypoxia makes vascular smooth muscle cells (VSMCs) responsive to placental growth factor (PlGF) through the induction of functional fms-like tyrosine kinase (Flt-1) receptors. The aim of this study was to investigate the molecular mechanisms involved in the PlGF effects on proliferation and contraction of VSMCs previously exposed to hypoxia (3% O2). In cultured rat VSMCs exposed to hypoxia, PlGF increased the phosphorylation of protein kinase B (Akt), p38 and STAT3; activation of STAT3 was higher than that of other kinases. In agreement with this finding, the proliferation of hypoxia-treated VSMCs in response to PlGF was significantly impaired by the p38 and the phosphatidylinositol 3-kinase inhibitors SB202190 and LY294002, respectively, and was almost completely prevented by AG490, a janus tyrosine kinase (JAK)/signal transducer and activator of transcription (STAT) inhibitor. Since hypoxia was able to reverse the vasorelaxant effect of PlGF into a vasoconstrictor response, the mechanism of this latter effect was also investigated. Significant Flt-1 activity was measured in isolated preparations from rat aorta exposed to hypoxia. Inhibitors of mitogen-activated protein kinase kinase, Akt and STAT3 induced a modest inhibition of the vasoconstrictor response to PlGF, while the p38 inhibitor SB202190 markedly impaired the PlGF-induced contractile response. These effects were selectively mediated by Flt-1 without any involvement of foetal liver kinase-1 receptors. These data are the first evidence that different intracellular pathways activated by Flt-1 receptor in VSMCs are involved in diverse biological effects of PlGF: while mitogen activated protein kinase kinase/extracellular signal regulated kinase(1/2) and JAK/STAT play a role in VSMC proliferation, p38 is involved in VSMC contraction. These findings may highlight the role of PlGF in vascular pathology.


Subject(s)
Aorta, Thoracic/drug effects , Myocytes, Smooth Muscle/drug effects , Pregnancy Proteins/pharmacology , Signal Transduction/drug effects , Vascular Endothelial Growth Factor Receptor-1/drug effects , Animals , Aorta, Thoracic/cytology , Aorta, Thoracic/metabolism , Cell Hypoxia , Cell Proliferation/drug effects , Cells, Cultured , Chromones/pharmacology , Dose-Response Relationship, Drug , Imidazoles/pharmacology , In Vitro Techniques , Male , Morpholines/pharmacology , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/metabolism , Myocytes, Smooth Muscle/metabolism , Phosphoinositide-3 Kinase Inhibitors , Phosphorylation , Placenta Growth Factor , Proto-Oncogene Proteins c-akt/metabolism , Pyridines/pharmacology , Rats , Rats, Wistar , STAT3 Transcription Factor/metabolism , Time Factors , Tyrphostins/pharmacology , Vascular Endothelial Growth Factor Receptor-1/metabolism , Vasoconstriction/drug effects , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , p38 Mitogen-Activated Protein Kinases/metabolism
6.
FEBS Lett ; 579(12): 2731-6, 2005 May 09.
Article in English | MEDLINE | ID: mdl-15862317

ABSTRACT

The exact phenotype and lineage of endothelial progenitor cells (EPCs) are still a matter of debate and different expansion protocols are used to obtain them. In this study, EPC expansion from peripheral blood mononuclear cells was analyzed within the first week of culture. Both the adherent and suspended cells, of which the latter usually discarded, were considered. We provide, for the first time, a systematic study of EPC phenotype and functional features within the first 3 days of culture. Moreover, within the 2nd day, both cellular fractions displayed a significant increase in endothelial marker expression which correlated with EPC properties.


Subject(s)
Cell Differentiation , Endothelial Cells/cytology , Leukocytes, Mononuclear/cytology , Phenotype , Scattering, Radiation , Stem Cells/cytology , Biomarkers/metabolism , Cell Lineage , Cell Movement , Cells, Cultured , Collagen/metabolism , Drug Combinations , Endocytosis , Endothelial Cells/physiology , Extracellular Matrix/metabolism , Flow Cytometry , Fluorescent Antibody Technique , Gene Expression , Humans , Immunohistochemistry , Immunophenotyping , Laminin/metabolism , Leukocytes, Mononuclear/physiology , Light , Proteoglycans/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Stem Cells/physiology , Time Factors
7.
Med Sci Monit ; 10(12): BR477-84, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15567979

ABSTRACT

BACKGROUND: The neuroprotective effect of N-(2-propynyl)2-(5-benzyloxy-indol)methylamine (PF 9601N), a novel MAO B inhibitor, and its metabolite FA 72 on the human neuroblastoma SHSY5Y cell line lesioned with (300 microM) dopamine was assessed and compared with that of 1-deprenyl assayed at identical experimental conditions. MATERIAL/METHODS: Using this experimental model, PF 961N showed a neuroprotective effect in a dose-dependent manner, and at a concentration of 10 pM a 20% recovery of cell viability was observed. However, the metabolite FA72 assayed under the same experimental conditions showed an increase in cell viability of nearly 50%. In the case of l-deprenyl, a concentration of 100 microM was necessary to recover only 10% of cell viability. RESULTS: This neuroprotective effect could be explained in terms of the antioxidant capacity of PF 9601N. In this context, the antioxidant capacities of the novel series of MAO inhibitors, PF 9601N and its analogues, were evaluated by their inhibition of the auto-oxidation of dopamine to melanin and by the dichlorofluorescein and 2-deoxyribose methods. CONCLUSIONS: All of these compounds have the basic structure of an indole ring in common, but show different substituents at different positions in it. The corresponding structure-activity relationship studies allowed us to conclude that the presence of a benzyloxy group, or a hydroxy or methoxy group, at position 5 of the indol ring enhanced these antioxidant characteristics, presenting a decreasing order of antioxidant activity of the primary > secondary > tertiary amines. The antioxidant properties of PF 9601 N would explain its neuroprotective effect observed in SHSY5Y cells lesioned with dopamine.


Subject(s)
Antioxidants/pharmacology , Antiparkinson Agents/pharmacology , Indoles/pharmacology , Neuroprotective Agents/pharmacology , Animals , Antioxidants/chemistry , Antioxidants/therapeutic use , Antiparkinson Agents/chemistry , Antiparkinson Agents/therapeutic use , Brain/drug effects , Brain/metabolism , Brain Chemistry , Cell Line, Tumor , Dopamine/pharmacology , Dose-Response Relationship, Drug , Humans , Indoles/therapeutic use , Melanins/biosynthesis , Monoamine Oxidase Inhibitors/chemistry , Monoamine Oxidase Inhibitors/pharmacology , Monoamine Oxidase Inhibitors/therapeutic use , Neuroblastoma , Neuroprotective Agents/chemistry , Neuroprotective Agents/therapeutic use , Oxidative Stress/drug effects , Parkinson Disease/drug therapy , Rats , Rats, Sprague-Dawley , Reactive Oxygen Species/analysis , Reactive Oxygen Species/metabolism , Selegiline/pharmacology , Tryptamines/pharmacology
8.
Am J Physiol Heart Circ Physiol ; 286(5): H1978-84, 2004 May.
Article in English | MEDLINE | ID: mdl-14693680

ABSTRACT

Vessel wall remodeling is a complex phenomenon in which the loss of differentiation of vascular smooth muscle cells (VSMCs) occurs. We investigated the role of rat macrophage chemoattractant protein (MCP)-1 on rat VSMC proliferation and migration to identify the mechanism(s) involved in this kind of activity. Exposure to very low concentrations (1-100 pg/ml) of rat MCP-1 induced a significant proliferation of cultured rat VSMCs assessed as cell duplication by the counting of total cells after exposure to test substances. MCP-1 stimulated VSMC proliferation and migration in a two-dimensional lateral sheet migration of adherent cells in culture. Endogenous vascular endothelial growth factor-A (VEGF-A) was responsible for the mitogenic activity of MCP-1, because neutralizing anti-VEGF-A antibody inhibited cell proliferation in response to MCP-1. On the contrary, neutralizing anti-fibroblast growth factor-2 and anti-platelet-derived growth factor-bb antibodies did not affect VSMC proliferation induced by MCP-1. RT-PCR and Western blot analyses showed an increased expression of either mRNA or VEGF-A protein after MCP-1 activation (10-100 pg/ml), whereas no fms-like tyrosine kinase (Flt)-1 receptor upregulation was observed. Because we have previously demonstrated that hypoxia (3% O2) can enhance VSMC proliferation induced by VEGF-A through Flt-1 receptor upregulation, the effects of hypoxia on the response of VSMCs to MCP-1 were investigated. Severe hypoxia (3% O2) potentiated the growth-promoting effect of MCP-1, which was able to significantly induce cell proliferation even at a concentration as low as 0.1 pg/ml. These findings demonstrate that low concentrations of rat MCP-1 can directly promote rat VSMC proliferation and migration through the autocrine production of VEGF-A.


Subject(s)
Chemokine CCL2/physiology , Mitosis/physiology , Muscle, Smooth, Vascular/cytology , Myocytes, Smooth Muscle/cytology , Vascular Endothelial Growth Factor A/physiology , Animals , Cell Division/drug effects , Cell Division/physiology , Cell Hypoxia/physiology , Cell Movement/drug effects , Cells, Cultured , Chemokine CCL2/pharmacology , Male , Muscle, Smooth, Vascular/physiology , Myocytes, Smooth Muscle/physiology , Rats , Rats, Wistar , Vascular Endothelial Growth Factor Receptor-1/metabolism
9.
J Neurochem ; 86(5): 1174-80, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12911625

ABSTRACT

The aim of the present investigation was to characterize the cytochrome P450 (CYP)-dependent metabolism of l-deprenyl by brain microsomal preparations obtained from two different animal models that have been extensively used in Parkinson's disease studies, namely monkey (Cercopithecus aethiops) and C57BL/6 mouse. In monkey brain microsomal fractions, the apparent Km values for methamphetamine formation from l-deprenyl were 67.8 +/- 1.0 and 72.0 +/- 1.6 microm, in the cortex and striatum, respectively. Similarly, for nordeprenyl formation from l-deprenyl, Km values in cortex and striatum were 21.3 +/- 3.2 and 27.3 +/- 4.0 microm, respectively. Both metabolic pathways appear to be more efficient in the cortex than in the striatum as the Vmax for microsomal preparation was lower in the striatum for the formation of both metabolites. The formation rate of l-methamphetamine was up to one order of magnitude greater than that of nordeprenyl. Inhibition analysis of both pathways in monkey brain suggested that l-methamphetamine formation is catalysed by CYP2A and CYP3A, whereas only CYP3A appears to be involved in nordeprenyl formation. With microsomal preparations from whole brain of C57BL/6 mice, the only l-deprenyl metabolite that could be detected was methamphetamine and the Km and Vmax values were similar to those determined in monkey cortex (53.6 +/- 2.9 microm and 33.9 +/- 0.4 pmol/min/mg protein, respectively). 4-Methylpyrazole selectively inhibited methamphetamine formation, suggesting the involvement of CYP2E1. In conclusion, the present study indicates that l-deprenyl is effectively metabolised by CYP-dependent oxidases in the brain, giving rise mainly to the formation of methamphetamine, which has been suggested to play a role in the pharmacological effects of the parent drug. The results also demonstrate that there are differences between species in CYP-dependent metabolism of l-deprenyl.


Subject(s)
Antiparkinson Agents/metabolism , Brain/metabolism , Cytochrome P-450 Enzyme System/metabolism , Microsomes/metabolism , Selegiline/metabolism , Animals , Antiparkinson Agents/pharmacokinetics , Biotransformation , Brain Chemistry , Cerebral Cortex/chemistry , Cerebral Cortex/metabolism , Chlorocebus aethiops , Corpus Striatum/chemistry , Corpus Striatum/metabolism , Cytochrome P-450 Enzyme Inhibitors , Enzyme Inhibitors/pharmacology , Isoenzymes/antagonists & inhibitors , Isoenzymes/metabolism , Mice , Mice, Inbred C57BL , Microsomes/chemistry , Oxidation-Reduction , Selegiline/pharmacokinetics , Species Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...